Introduction
Neuroblastoma is a pediatric tumor of the peripheral nervous system arising from primordial neural crest cells (Castleberry, 1997; Cianfarani and Rossi, 1997) . Neuroblastic tumors account for 8-10% of all pediatric cancers and are second in incidence among solid tumors in children (Philip, 1992; Castleberry, 1997) . Neuroblastoma metastases form through dissemination of transformed cells into the bloodstream and local invasion into bone, leptomeninges, and other organs (Philip, 1992; Tanabe et al., 1995) . Although neuroblastoma is treatable, advanced-stage metastatic disease is largely incurable using current treatment protocols (Philip, 1992) . There are several hypotheses for the pathogenesis of neuroblastoma, but the predominant explanation is improper differentiation of those primordial neural crest cells forming the sympathetic nervous system tissues including the adrenal medulla and the spinal sympathetic ganglia (Castleberry, 1997; Cianfarani and Rossi, 1997) .
The most common genetic abnormalities associated with neuroblastoma are the deletion of the short arm of chromosome 1 and MYCN amplification (Corvi et al., 1997) . Two types of chromosome 1 deletions are observed: a short deletion at 1p36.2-3, and a larger deletion, which is associated with more aggressive disease and MYCN amplification, at 1p35-36 (Kaghad et al., 1997) . MYCN amplification is associated with advanced-stage disease (Brodeur et al., 1984; Maris and Matthay, 1999) and is present primarily in undifferentiated neuroblasts . To date, MYCN amplification is the only reliable prognostic indicator for neuroblastoma (Corvi et al., 1997) . Increased MYCN gene copy number indicates poor patient prognosis (Brodeur et al., 1984; Schwab et al., 1984; Bordow et al., 1998) , and overexpression of the MYCN gene product, N-Myc, leads to an increased tumorigenic phenotype in neuroblastoma cell lines (Jasty et al., 2001) . These findings have led investigators to explore the effects of N-Myc expression in neuroblastoma.
N-Myc overexpression not only leads to an increased tumorigenic phenotype in neuroblastoma cells, but paradoxically leads to an increased drug-induced apoptotic cell death (Fulda et al., 2000) . Apoptosis occurs in tumors around areas of necrosis and in response to chemotherapeutic drug, or radiation, treatment (Kerr et al., 1994) . Apoptosis is also detected in vivo in the karyorrhectic cells of neuroblastoma tumors (Koizumi et al., 1995) . Treatment-resistant tumors, including advanced-stage neuroblastomas, may have changes in apoptotic regulatory proteins giving them a survival advantage (Hickman, 1992; Gelbard et al., 1997) . Apoptosis regulatory proteins affected may include Bcl-2 family members or caspases. Advancedstage tumors express abundant Bcl-2 protein (Koizumi et al., 1995) ; therefore, investigators have subsequently tried to establish Bcl-2 as a prognostic indicator for neuroblastoma, but the results remain ambiguous (Reed et al., 1991; Castle et al., 1993; Hoehner et al., 1995; Ikeda et al., 1995; Mejia et al., 1998) . What is clear is that Bcl-2 and the closely related family member Bcl-X L confer apoptotic resistance when overexpressed in neuroblastoma cell lines (Dole et al., 1994 (Dole et al., , 1995 . These studies suggest that the regulation of apoptosis is important in neuroblastoma tumorigenesis and progression.
Our previous work demonstrated serum-withdrawal and mannitol-induced apoptosis in SHEP neuroblastoma cells, preventable through type I insulin-like growth factor (IGF-IR) activation or Bcl-2 overexpression . N-Myc overexpression leads to increased expression of the IGF-IR and increased tumorigenic properties in neuroblastoma cells (Jasty et al., 2001) . Therefore, the current study examines the effect of N-Myc overexpression on apoptosis and IGF-IR-mediated survival signaling in SHEP human neuroblastoma cells. N-Myc enhances both serum-withdrawal and mannitol-induced apoptosis. Furthermore, N-Myc prevents IGF-I rescue of SHEP cells in mannitolcontaining medium. N-Myc alone has little effect on IGF-IR-mediated signaling. However, phosphorylation of the survival protein Akt is increased in cells expressing Bcl-2 alone or N-Myc and Bcl-2. In addition, N-Myc overexpression decreases b1 integrin expression, which indicates a less-differentiated phenotype and may lead to an anoikis-like apoptotic death. Finally, when b1 integrin is re-expressed in N-Myc-transfected cells, these cells become resistant to mannitol-mediated apoptosis. Therefore, N-Myc overexpression in SHEP cells likely results in less-differentiated neuroblastoma cells better able to proliferate, yet more susceptible to apoptosis.
Results

N-Myc enhances apoptosis in SHEP neuroblastoma cells
Our laboratory is interested in the role of growth factors and adhesion proteins in neuroblastoma progression Meyer et al., 2001) . We have previously shown that N-Myc and Bcl-2 coexpression enhances tumorigenic properties in SHEP neuroblastoma cells (Jasty et al., 2001) . Furthermore, N-Myc expression leads to increased IGF-IR expression (Jasty et al., 2001) . The IGF system promotes tumor progression in several ways, including proliferation, motility, invasion, and survival, and prevents mannitol-induced apoptotic cell death in SHEP neuroblastoma cells .
In the current study, we investigated the effect of NMyc overexpression and IGF-I treatment on serumwithdrawal and mannitol-induced apoptosis. SHEP cells expressing either control vector (SHEP/Vector), N-Myc (SHEP/N-Myc), Bcl-2 (SHEP/Bcl-2), or N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2) were previously created and characterized (Jasty et al., 2001) . SHEP cells do not normally express detectable levels of N-Myc protein, and the stable transfectants chosen for analysis in our previous and current studies express high levels of NMyc, comparable to the MYCN-amplified, highly tumorigenic KCNR cell line (Jasty et al., 2001) . We have previously shown that mannitol induces apoptosis in SHEP neuroblastoma cells by activating caspases within 3 h, causing mitochondrial membrane depolarization by 18 h, and DNA fragmentation and subsequent morphological changes associated with apoptosis by 24 h . Therefore, we analysed the effect of N-Myc overexpression on apoptosis after 24 h of either serum deprivation or mannitol treatment. In total, 13% of SHEP/Vector cells undergo apoptosis in serum-withdrawal conditions, which increases to 42% with mannitol treatment (Figure 1 ). When N-Myc is expressed (SHEP/N-Myc cells), the number of apoptotic cells significantly increases with both serum-withdrawal and mannitol treatment (42 and 72% respectively, Po0.05). Morphological characteristics of apoptosis, including chromatin condensation, membrane blebbing, and the formation of apoptotic bodies, are also increased in SHEP/N-Myc cells in either serum-withdrawal or mannitol-containing conditions, supporting the data presented above (data not shown). The addition of 10 nm IGF-I protects a significant portion of the We have previously shown that Bcl-2 overexpression rescues virtually all SHEP neuroblastoma cells from mannitol-mediated apoptosis . In the current experiment, Bcl-2 also protects the majority of cells from apoptosis when N-Myc is overexpressed, with less than 5% of SHEP/N-Myc/Bcl-2 cells undergoing apoptosis in any condition (Figure 1 ).
N-Myc and Bcl-2 coexpression enhance IGF-IR-mediated signaling IGF signaling through the IGF-IR mediates the protection of diverse cell types from apoptosis and plays a role in many aspects of tumorigenesis (Leventhal et al., 1999) . Two principal pathways mediate the tumorigenic effects of IGF downstream from the IGF-IR, the phosphatidylinositol 3-kinase (PI-3 K) pathway and the mitogen-activated protein kinase (MAPK) pathway (Baserga, 1994) . We have previously reported that the PI-3 K pathway is important for both IGFmediated protection and cellular motility (Cheng et al., 2000; Meyer et al., 2001; van Golen et al., 2001) . Therefore, we began by examining the effect of N-Myc and Bcl-2 on the PI-3 K pathway, given the effect of these proteins on apoptosis. To examine the effect of NMyc and Bcl-2 on IGF signaling, SHEP cells, SHEP/ Vector, SHEP/N-Myc, SHEP/Bcl-2, and SHEP/N-Myc/ Bcl-2 cells were exposed to IGF-I for 30 min, a time point at which there is maximum IGF-IR signaling in SHEP cells . Overexpression of N-Myc has little effect on IGF-mediated phosphorylation of Akt, a downstream target of PI-3 K implicated in cell survival. However, Bcl-2 overexpression increases IGF-I-mediated Akt phosphorylation by 1.9-fold ( Figure 2a ). Expression of both N-Myc and Bcl-2 further increases Akt phosphorylation to 4.1-fold ( Figure 2a ) with only a slight increase in Akt protein levels. Therefore, these data suggest an increase in PI-3 K activity in cells expressing Bcl-2 alone or both N-Myc and Bcl-2.
Activation of the MAPK pathways results in the phosphorylation of the extracellular-related kinases (Erks). Our laboratory has reported that cellular differentiation is dependent upon Erk activity in SH-SY5Y neuroblastoma cells (Kim et al., 1997) . Furthermore, Erks 1 and 2 (Erk-1/2) do not play a role in IGF-IR-mediated survival signaling and may even promote apoptosis in neuroblastoma cells ). In the current study, expression of either NMyc or Bcl-2 alone slightly enhances Erk-1/2 protein and phosphorylation levels when compared to control (Figure 2b ). When the MAPK pathway is blocked using the inhibitor PD98059, mannitol-mediated apoptosis is significantly decreased (Po0.05) in both vector and NMyc-transfected SHEP cells (Figure 2c ). These data suggest that increased signaling through the MAPK pathway may promote apoptosis in these cells. Given the relatively slight effects of N-Myc overexpression on these signaling molecules, however, we began searching for other molecules responsible for the increased apoptosis in N-Myc-overexpressing cells.
N-Myc expression decreases b-1 integrin expression in SHEP neuroblastoma cells
Anoikis is a type of apoptosis induced by detachment of anchorage-dependent cells from extracellular matrix (ECM) (Valentinis et al., 1998; Kumar, 1998) . Therefore, integrin ligand binding is important for survival signaling in a variety of tumor types (Kumar, 1998) . Cellular effects mediated by growth factors, including IGF-I, may also be modulated by integrin ligand binding and subsequent intracellular signaling through the b subunit (Danen and Yamada, 2001) .
Previous investigators have shown a decrease in b1 integrin expression in neuroblastoma cells transfected with N-Myc (Flickinger et al., 1994; Judware and Culp, 1995) . Given the crosstalk between integrin and IGF-IR signaling in other systems, a decrease in b1 integrin could alter IGF-I-related survival and differentiation signaling in neuroblastoma cells. Therefore, we examined the expression of b1 integrin in SHEP cells expressing N-Myc, Bcl-2, or both. SHEP/vector cells have abundant b1 integrin expression (Figure 3a) . However, N-Myc-overexpressing cells, with or without Bcl-2 present, display a decreased amount of b1 integrin expression. Bcl-2 expression alone does not affect b1 integrin, suggesting that this effect is specific for N-Myc. b1 integrin expression modulates both cell spreading on ECM and both cell-cell and cell-ECM adhesion. Those SHEP cells overexpressing N-Myc do not display a dramatically different morphology in comparison with vector control cells, although they are typically more narrow and are less adhesive (unpublished observations).
To analyse b1 integrin expression, a b1 adhesion assay was performed using plates precoated with anti-b1 antibodies (Figure 3b) . SHEP/N-Myc cells show slightly decreased levels of adhesion to anti-b1-coated plates. SHEP cells expressing Bcl-2 alone have increased b1 integrin-mediated adhesion, suggesting increased b1 integrin expression; however, if N-Myc is coexpressed, the levels of binding are again decreased (Figure 3b ). This assay demonstrates that N-Myc decreases, whereas Bcl-2 alone increases, b1 integrin expression and/or binding affinity.
We have recently shown that overexpression of NMyc and Bcl-2 in differentiated neuroblastoma cells induces proliferation, anchorage-independent growth, angiogenesis, and tumor formation in nude mice (Jasty et al., 2001) . We also know that SHEP/N-Myc/Bcl-2 cells have decreased b1 integrin expression and increased IGF-IR expression (this study and Jasty et al., 2001 ). Our hypothesis is that more tumorigenic neuroblastoma cells have decreased b1 integrin expression, which leads to a less-differentiated phenotype. Given the results from these studies, we examined several neuroblastoma cell lines for b1 integrin and IGF-IR expression. We chose neuroblastoma cell lines with different degrees of tumorigenicity for this experiment: SHEP, SH-SY5Y, SK-N-AS, SK-N-SH, IMR32, and SHEP/N-Myc cells. b1 integrin expression is high among those cells with a more differentiated phenotype, including the SHEP and SK-N-AS cells, while expression is low in those cell lines displaying increased tumorigenic potential, including SHEP/N-Myc, SH-SY5Y, and IMR32 cells (Figure 4) . In contrast, IGF-IR expression is higher among more tumorigenic cell lines (Figure 4 ). These data support our hypothesis that b1 integrin expression is strongly associated with neuroblastoma tumorigenicity, so that high b1 integrin expression leads to highly differentiated neuroblastoma cells while low b1 integrin expression leads to poorly differentiated, that is, undifferentiated, neuroblastoma cells. .5% SDS-PAGE gel, transferred to nitrocellulose, and Western immunoblotted for (a) phospho-p44/p42 Erk (P-Erk-1/2) and p44/p42 Erk (Erk-1/2) or (b) phospho-(S473) Akt (P-Akt) and Akt. Relative expression is the mean pixel density for an equal portion of each band as determined using densitometry (described in Materials and methods). (c) Nearly confluent SHEP/Vector or SHEP/N-Myc cells were exposed to either DMEM alone (0 mm) or 300 mm mannitol (300 mm) with or without 10 mm PD98059 (PD) or 50 mm LY294002. After 24 h, cells were collected, fixed, and prepared for flow cytometry as described above. Results are the mean+s.e.m. for three separate experiments. An asterisk (*) represents a value significantly lower (Po0.05) than the percent apoptosis in the corresponding cell type treated with mannitol N-Myc overexpression leads to increased apoptosis and decreased b1 integrin expression in SK-N-AS cells (Figure 6a ). Those cells expressing the b1 integrin show highly increased cell spreading and membrane ruffling along the cell edges and grow very slowly compared to control cells (unpublished observations). The SHEP/N-Myc/ vector or SHEP/N-Myc/b1 cells were then exposed to high mannitol conditions and apoptosis measured. In each b1 integrin-expressing clone, the percentage of cells undergoing apoptosis was less than 13% (Figure 6b ), suggesting that b1 integrin overexpression prevents apoptosis in these cells. Discussion N-Myc expression is a prognostic factor for neuroblastoma (Corvi et al., 1997) , with increased N-Myc expression through MYCN gene amplification leading to poor patient prognosis (Brodeur et al., 1984; Schwab et al., 1984) . N-Myc is a transcription factor known to repress several adhesion-related genes (Grandori et al., 2000; Gross et al., 2000) , and N-Myc leads to modulation of IGF action through increased IGF-IR receptor expression and decreased IGF-binding protein expression (Chambery et al., 1999; Jasty et al., 2001 ). Therefore, N-Myc may modulate neuroblastoma tumorigenicity and apoptosis through interference with integrin-mediated cell adhesion and IGF signaling through the IGF-IR.
IGF-I and -II and IGF-IR and -IIR are expressed in both neuroblastoma cell lines and primary tumors (Martin et al., 1992; Sullivan et al., 1995) . IGF expression is present in all stages of primary neuroblastoma tumors, suggesting a pivotal role in neuroblastoma tumorigenesis (Sullivan et al., 1995) . Inhibition of IGF-IR expression using antisense strategies can inhibit tumor growth and induce regression of neuroblastoma tumors in mice (Liu et al., 1998) . integrin cells were exposed to 300 mm mannitol for 24 h followed by flow cytometry analysis as previously described Furthermore, IGF-I induces early changes associated with migration in neuroblastoma cells, such as process formation and random motility Leventhal et al., 1999) , and IGF-I and IGF-IR expression protect neuroblastoma cells from apoptosis (Singleton et al., 1996a, b; Matthews et al., 1997; van Golen et al., , 2001 N-myc overexpression in SK-N-SH neuroblastoma cells increases IGF-II, IGF-IR, IGFBP-2, and IGFBP-4, while decreasing IGFBP-6 expression (Chambery et al., 1999) . Collectively, these data support the generally held concept that the IGF family of ligands and receptors promote neuroblastoma tumor formation, survival, metastasis, and resistance to clinical treatments, leading to a more aggressive and untreatable disease state.
Given the role of the IGF-IR in neuroblastoma survival and the effect of N-Myc on IGF-IR expression, we examined the effect of N-Myc on apoptosis in SHEP neuroblastoma cells. N-Myc enhances apoptosis and prevents IGF-I rescue of SHEP cells, despite the upregulation of the IGF-IR. Although N-Myc-expressing cells have increased growth and increased in vitro tumorigenic potential (Jasty et al., 2001 ), several reports demonstrate enhanced apoptosis in the presence of NMyc. Drug-induced apoptosis induced by doxorubicin increases in SHEP neuroblastoma cells (Fulda et al., 2000) . N-Myc also increases the number of hypoxiainduced apoptotic cells in SH-EP 007 and WAC1 human neuroblastoma cell lines (Rossler et al., 2001) . c-Myc also induces cell death through several apoptotic pathways, which are modulated through the action of cytokines and growth factors, including IGF-I (Prendergast, 1999). Therefore, a similar mechanism may be true for N-Myc.
Given that N-Myc overexpression prevents IGF rescue of SHEP cells from mannitol-induced apoptosis, we examined IGF signaling in SHEP/N-Myc cells. IGF-I acting through the IGF-IR signals through two predominant pathways, the PI-3 K pathway and the MAPK pathway (Baserga, 1994) , leads to phosphorylation of Akt and Erk-1/2, respectively. However, N-Myc expression has little effect on IGF signaling, although coexpression of N-Myc and Bcl-2 results in a dramatic increase in Akt phosphorylation on serine 473. Bcl-2 overexpression alone enhances Akt phosphorylation, consistent with its antiapoptotic effect, but fails to reduce Erk-1/2 phosphorylation. Akt also suppresses apoptosis induced by c-myc overexpression downstream from the IGF-IR (Rohn et al., 1998) . We have previously shown that the PI-3K/Akt pathway is important for neuroblastoma cell survival (Cheng et al., 2000; van Golen et al., 2001 ) while Erk activation is important for differentiation (Kim et al., 1997) . N-Myc inhibition using antisense oligonucleotides induces differentiation in S-type neuroblastoma cells and decreases Bcl-2 protein levels (Galderisi et al., 1999) . Therefore, these data suggest that N-Myc and Bcl-2 may cooperate to produce a less-differentiated phenotype in SHEP neuroblastoma cells through action on the PI-3 K pathway.
IGF-IR signaling is modulated through the action of b1 integrins (Shakibaei et al., 1999) . Furthermore, disruption of b1 integrin adhesion in neuroblastoma cells leads to apoptosis (Bonfoco et al., 2000) . Finally, soluble ECM components and growth factors rescue neuroblastoma cells from apoptosis induced under nonadherent conditions (Bozzo et al., 1997) . Therefore, b1 integrin expression and adhesion were measured in SHEP cells overexpressing N-Myc, Bcl-2, or both. b1 integrin expression is decreased in SHEP cells overexpressing N-Myc, even in the presence of Bcl-2. These data support previous reports that transfection and overexpression of N-Myc leads to a loss of a2, a3, and b1 integrins (Flickinger et al., 1994; Judware and Culp, 1995) . N-Myc may therefore enhance apoptosis and prevent IGF-I rescue without affecting IGF signaling by disrupting b1 integrin signaling. We also protect cells from mannitol-mediated apoptosis through b1 integrin overexpression, supporting this claim.
Our idea is also supported by several pieces of evidence in other forms of cancer. Tamoxifen-induced apoptosis in MCF-7 breast cancer cells induces a 50% depletion of b1 integrin (Dabrowska et al., 2001) . Prevention of a6b1 expression in MDA-MB-435 metastatic breast cancer cells induces apoptosis and prevents metastasis (Wewer et al., 1997) . Activation and expression of b1 integrin receptors inhibits apoptosis in lymphocytes (Stallmach et al., 2001) , mesangial cells (Mooney et al., 1999) , and esophagial squamous cell carcinoma cells (Miller and Veale, 1902) . Finally, in human neuroblastoma cells, antisense oligonucleotides to the b1 integrin or disruption of adhesion to matrix promotes apoptosis (Rozzo et al., 1997) . Therefore, the decrease in b1 integrin induced by N-Myc overexpression in the current study may promote apoptosis and a less-differentiated phenotype in neuroblastoma cells.
To further support a role for decreased b1 integrin expression in neuroblastoma tumorigenesis, several cell lines were tested for both b1 integrin and IGF-IR expression. In those cell lines with a less-differentiated, more tumorigenic phenotype, b1 integrin expression is low and IGF-IR expression is high, while the reverse is true for less tumorigenic cells. Our data in cell lines are supported by reports in primary neuroblastoma tumors. In these tumors, expression of several integrin receptors, including a4b1 and a6b4, is found primarily in N-Mycnegative tumors with better prognosis. In contrast, a1b1 and a3b1 are typically absent in N-Myc-positive tumors with poor prognosis (Favrot et al., 1991) .
Cell lines naturally expressing higher levels of N-Myc show decreased overall integrin expression. In parallel, the expression of b1 integrin protein correlates with attached, spread cells, while the absence of b1 integrin promotes detachment and rounding of the cells (Judware and Culp, 1995) . The small amount of b1 integrin expressed in N-Myc-overexpressing neuroblastoma cell lines reaches the cell surface, but fails to form heterodimers with a2 or a3 subunits to produce functional integrin receptors (Judware and Culp, 1997) . In several neuroblastoma cell lines, differentiation leads to increased expression of a1b1, a2b1, and a3b1 integrin receptors, regardless of the stimuli (Rossino et al., 1991; Rozzo et al., 1993) . Overexpression of the DR-nm23 gene, suggested to play a role in cellular differentiation, leads to increased ECM deposition and a dramatic increase in b1 integrin expression in multiple neuroblastoma cell lines (Amendola et al., 1997) . Retinoic-acidexposed neuroblastoma cells show increased DR-nm23 levels, increased neurite outgrowth, and increased b1 integrin expression (Amendola et al., 2001) . Collectively, these studies suggest that increased neuroblastoma differentiation correlates with increased integrin subunit expression. Conversely, more highly metastatic, poorer prognosis undifferentiated neuroblastomas have decreased integrin expression, which potentially results in abnormal or loss of integrin-mediated signaling.
In conclusion, N-Myc and Bcl-2 likely produce a more tumorigenic phenotype in neuroblastoma cells through both increases in IGF-IR expression and downstream PI-3 K signaling and the modulation of integrin expression. Abnormal integrin expression patterns and signaling may lead to neuroblastoma tumor formation and/or progression through a disruption of normal differentiation pathways (Favrot et al., 1991; Gladson et al., 1996) . Differentiated low-grade neuroblastoma tumors have a better prognosis, suggesting a role for differentiation-inducing therapies in high-grade neuroblastoma (George et al., 2001) . We are currently examining the effect of b1 integrin expression and signaling on other aspects of tumorigenesis and differentiation in human neuroblastoma.
Materials and methods
Materials
Tissue culture plastic was obtained from Corning and BD Biosciences (Corning: Coming, NY, USA; BD Biosciences: Bedford, MA, USA). Biocoat cellware precoated with fibronectin was purchased from BD Biosciences (Bedford, MA, USA). Dulbecco's modified Eagle's medium (DMEM), Hank's balanced salt solution (HBSS), lipofectamine 2000, and trypsin-EDTA were purchased from Gibco BRL (Gaithersburg, MD, USA). Calf serum (CS) was purchased from Hyclone (Logan, UT, USA). Antibodies were purchased from the following: all secondary antibodies and IGF-IR antibody, Santa Cruz Biotechnology (Santa Cruz, CA, USA); Akt and p44/42 Erk antibodies, Cell Signaling Technology (Hercules, CA, USA); b1 integrin monoclonal antibody, Transduction Laboratories (San Diego, CA, USA); and GAPDH monoclonal antibody. Western immunoblotting reagents were purchased from Bio-Rad Laboratories (Hercules, CA, USA), Amersham Pharmacia Biotech (Piscataway, NJ, USA), or Cell Signaling Technology (Beverly, MA, USA) as described in the Western immunoblotting section. LY294002 and PD98059 were purchased from Calbiochem (La Jolla, CA, USA). All other chemicals mentioned were purchased from Sigma Chemical Company (St Louis, MO, USA) unless otherwise stated.
Cell culture
SHEP human neuroblastoma cells were grown in DMEM+10% CS at 371C in a humidified atmosphere with 10% CO 2 . SHEP cells transfected with vector alone (SHEP/ vector cells), N-Myc (SHEP/N-Myc cells), Bcl-2 (SHEP/Bcl-2 cells), or N-Myc and Bcl-2 (SHEP/N-Myc/Bcl-2 cells) (Jasty et al., 2001) were maintained in DMEM+10% CS+250 mg/ml G418 (Gibco BRL). These constructs and transfection into SHEP cells were as previously described (Jasty et al., 2001) . Cells were routinely subcultured through removal of the cells from the plates with trypsin-EDTA.
b1-integrin-overexpressing cell formation
A V5 epitope tagged b1 integrin construct in pCDNA3.1 containing zeocin resistance was purchased from Resgen (Carlsbad, CA, USA) SHEP/Vector and SHEP/N-Myc cells were transfected with the b1 integrin construct or with a control pCDNA3.1zeo vector using lipofectamine 2000 according to the manufacturer's protocol. Cells were selected in DMEM+10 CS+250 mg/ml zeocin, and single-cell clones selected using serial dilution. Resultant clones were selected for 1 month prior to use. Transfected SHEP/Vector cells failed to grow, and were thus not used in our current study. Successful transfection of the b1 integrin construct was tested by Western immunoblotting for the V5 tag using an HRPconjugated anti-V5 antibody (Invitrogen, Carlsbad, CA, USA).
Western immunoblotting
Western blot analyses were performed as previously described (Leventhal et al., 1995) . Briefly, cell lysates were collected using RIPA buffer (20 mm Tris (pH 7.4), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mm sodium orthovanadate, 0.1 trypsin inhibitor units/ml, 10 mg/ml leupeptin, and 100 mg/ml PMSF). Protein concentrations were determined in both whole-cell lysates and concentrated media using the Bio-Rad DC protein assay kit. Protein (70 mg) were loaded and run on an SDS-PAGE gel prepared with Bio-Rad gel reagents. After transfer to nitrocellulose membranes, the membranes were incubated with the indicated primary antibody overnight at 41C. All membranes were further incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology, 1 : 2000 dilution) for 1 h, developed with Lumiglo Chemiluminescent Detection Reagents (Cell Signaling), and exposed to film (Hyperfilm-ECL, Amersham). Densitometry was performed by measuring pixel density in a defined region of each band using Scion Image for Windows software, which is based upon NTH Image for Mac (Scion Corporation). Blots shown are one of three independent experiments performed.
Flow cytometry
Quantitative measurements of apoptosis were performed using analysis of DNA content by flow cytometry (Matthews and Feldman, 1996; Singleton et al., 1996a) . Cells were plated in six-well tissue culture plates and grown to near confluence. After 4 h of serum deprivation, cells were incubated in experimental conditions and collected using trypsinization at the indicated times. After collection, cells were rinsed in HBSS, fixed in ice-cold 70% ethanol, and stored at 41C. Cells were stained for 2-12 h with 18 mg/ml propidium iodide (PI) containing 40 mg/ml RNAse A at 41C, then analysed using an Epics Elite flow cytometry system (Coulter Cytometry, Hialeah, FL, USA). DNA content of the PI-stained cells was measured and separated into phases of the cell cycle based upon PI fluorescence. Percent apoptotic cells was taken as %-sub-G 0 DNA, and results are expressed as the mean of three separate experiments7the standard error of the mean (s.e.m.).
Integrin binding assays
Cellular adhesion mediated by b1 of integrin was measured using an Integrin-Mediated Cell Adhesion Kit from Chemicon International (Temecula, CA, USA). Each kit was performed according to the manufacturer's published protocol. Briefly, a cell suspension containing 350 000 cells/ml in PBS detached from the plate using 5 mm EDTA was prepared. Cell suspension (100 ml) was added to the control plate and the 96-well capture plate. The capture plate contained a monoclonal antibody against human b1 immobilized to the plate with goat anti-mouse antibody. Cells were incubated on the plate for 2 h, rinsed with PBS containing 1 mm Ca 2+ /Mg 2+ . After rinsing, cells were stained for 5 min using the provided cell stain solution, rinsed five times, and air-dried. Wells were then incubated in the provided extraction buffer for 5 min, and absorbance was read at a wavelength of 560 nm using a LabSystems Fluoroskan Ascent FL fluorimeter (LabSystems, Franklin, MA, USA). Results are presented as the mean optical density7s.e.m. relative to control.
